SCHEDULE: Alzamend Neuro Major Shareholder Updates Beneficial Ownership and Reports Recent Stock Sales

Milton C. Ault, III and affiliated entities have updated their beneficial ownership in Alzamend Neuro, Inc., reporting a combined 18.5% stake and recent sales of common stock by Ault Lending, LLC.

Summary

• Milton C. Ault, III, along with Hyperscale Data, Inc., Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC, collectively reported beneficial ownership in Alzamend Neuro, Inc. (AZNM).
• Milton C. Ault, III beneficially owns 706,321 shares, representing approximately 18.5% of the common stock.
• Hyperscale Data, Inc. and Ault Lending, LLC each beneficially own 693,349 shares and 693,337 shares respectively, both representing approximately 18.1% of the common stock.
• Ault Life Sciences, Inc. beneficially owns 11,068 shares (0.4%), and Ault Life Sciences Fund, LLC beneficially owns 61 shares (0.0%).
• Other reporting persons, including William B. Horne, Henry C.W. Nisser, Kenneth S. Cragun, and David J. Katzoff, hold smaller percentages, primarily through direct shares and exercisable stock options.
• The aggregate percentage of shares reported beneficially owned is based on 3,139,861 shares outstanding as of July 30, 2025.
• Ault Lending, LLC converted 332.75528 shares and 232 shares of Series B Convertible Preferred Stock into common stock on July 23, 2025, and July 30, 2025, respectively, at a price of $1,000.00 per preferred share.
• Ault Lending, LLC sold a total of 243,429 shares of common stock between July 23, 2025, and July 31, 2025, at prices ranging from $2.2155 to $2.9502 per share.
• The aggregate purchase price for 8,260 shares and warrants exercisable into 23,334 shares owned by Ault Lending was approximately $24,446,080, including $1.4 million for marketing and brand development services.
• An additional 1,535.24 shares of Series B convertible preferred stock and warrants for 2,470 shares (not currently exercisable) were acquired by Ault Lending for approximately $1,535,245.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the significant sales of common stock by a major beneficial owner, Ault Lending, LLC, which could imply a reduction in confidence or a strategic shift by the holder.

Negatives

• Ault Lending, LLC, a significant beneficial owner, sold a total of 243,429 shares of common stock over a period of six trading days, indicating a reduction in its direct common stock holdings.

Risks

• Warrants held by Ault Lending, LLC for 2,470 shares of common stock are not currently exercisable due to a beneficial ownership blocker limitation provision contained therein, limiting immediate liquidity or conversion.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This filing is a routine update on beneficial ownership and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sectors.

Related Party Transactions

• Ault Lending, LLC acquired 691 shares of Alzamend Neuro common stock in exchange for marketing and brand development services provided by Hyperscale Data, Inc., its parent entity.

Stakeholder Impact

• Shareholders may view the significant sales by a major beneficial owner (Ault Lending, LLC) as a negative signal, potentially impacting investor confidence and the company's stock price.
• The beneficial ownership structure, with Milton C. Ault, III and affiliated entities holding a substantial stake, indicates continued influence over the company's strategic direction.

Key Dates

Recommendation

The filing indicates significant sales of common stock by a major beneficial owner, Ault Lending, LLC. While this is not a direct reflection of the company's operational performance, such divestment by a key stakeholder can create downward pressure on the stock price and may signal a lack of conviction or a need for liquidity from the selling entity. Investors should hold and monitor for further developments or explanations regarding these sales, as they introduce an element of caution without necessarily indicating a fundamental deterioration of the company's prospects.

Keywords

Alzamend Neuro, AZNM, Schedule 13D, Beneficial Ownership, Milton C. Ault III, Hyperscale Data, Ault Lending, Stock Sales, SEC Filing, Corporate Governance, Investment